RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice

Molecular Pharmacology

Volumn 79, Issue 6, 2011, Pages 953-963

  Wei, Jie ^a   Jones, Jeffrey ^a   Kang, Jing ^a   Card, Ananda ^a   Krimm, Michael ^a   Hancock, Paula ^b   Pei, Yi ^b   Ason, Brandon ^a   Payson, Elmer ^a   Dubinina, Natalya ^a   Cancilla, Mark ^a   Stroh, Mark ^b   Burchard, Julja ^a   Sachs, Alan B ^a   Hochman, Jerome H ^b   Flanagan, W Michael ^a   Kuklin, Nelly A ^a  

^a Sirna Therapeutics Inc   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ARGONAUTE 2 PROTEIN; LUCIFERASE; MESSENGER RNA; SJOGREN SYNDROME ANTIGEN B; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DOSE RESPONSE; GENE SILENCING; GENE TARGETING; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RNA BINDING; RNA INTERFERENCE; TRANSGENIC MOUSE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; GENE SILENCING; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 79956311068     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.070409     Document Type: Article

References (40)

1. Adams BD, Claffey KP, and White BA (2009) Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 150:14-23.
2. Bartlett DW and Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322-333. (Pubitemid 43160055)
3. Bartlett DW and Davis ME (2007) Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 97:909-921. (Pubitemid 47051060)
4. Boland A, Tritschler F, Heimstädt S, Izaurralde E, and Weichenrieder O (2010) Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein. EMBO Rep 11:522-527.
5. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33:e179.
6. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, and Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-1070.
7. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, Nechev L, Murugaiah V, Van Vliet A, Vaishnaw AK, et al. (2008) Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 77:225-231.
8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498. (Pubitemid 32494397)
9. Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, and Duker G (2009) Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 14:358-372.
10. Gilmore IR, Fox SP, Hollins AJ, and Akhtar S (2006) Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 3:147-155
11. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, and Kay MA (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541. (Pubitemid 44050158)
12. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. Rna 12:1197-1205.
13. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, et al. (2007) Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449:745-747. (Pubitemid 47552094)
14. Leclerc GM, Boockfor FR, Faught WJ, and Frawley LS (2000) Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques 29:590-591, 594-596, 598 passim.
15. Lima WF, Wu H, Nichols JG, Sun H, Murray HM, and Crooke ST (2009) Binding and cleavage specificities of human Argonaute2. J Biol Chem 284:26017-26028.
16. -ΔΔCT) method. Methods 25:402-408.
17. Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, et al. (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107:1864-1869.
18. Martin SE, Jones TL, Thomas CL, Lorenzi PL, Nguyen DA, Runfola T, Gunsior M, Weinstein JN, Goldsmith PK, Lader E, et al. (2007) Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 35:e57.
19. Matranga C, Tomari Y, Shin C, Bartel DP, and Zamore PD (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123:607-620. (Pubitemid 41608464)
20. Meibohm B and Derendorf H (2002) Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91:18-31. (Pubitemid 34074464)
21. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, and Tuschl T (2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15:185-197. (Pubitemid 38950966)
22. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, et al. (2005a) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41:1349-1356. (Pubitemid 40770288)
23. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, et al. (2005b) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007. (Pubitemid 41114035)
24. Parker JS, Roe SM, and Barford D (2006) Molecular mechanism of target RNA transcript recognition by Argonaute-guide complexes. Cold Spring Harb Symp Quant Biol 71:45-50.
25. Pei Y, Hancock PJ, Zhang H, Bartz R, Cherrin C, Innocent N, Pomerantz CJ, Seitzer J, Koser ML, Abrams MT, et al. (2010) Quantitative evaluation of siRNA delivery in vivo. RNA 16:2553-2563.
26. Pei Y and Tuschl T (2006) On the art of identifying effective and specific siRNAs. Nat Methods 3:670-676. (Pubitemid 44275732)
27. Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, and Kaelin WG Jr (2003) Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2:297-302.
28. Scherr M and Eder M (2007) Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 6:444-449. (Pubitemid 46393448)
29. Sepp-Lorenzino L and Ruddy M (2008) Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides. Clin Pharmacol Ther 84:628-632.
30. Somoza A, Terrazas M, and Eritja R (2010) Modified siRNAs for the study of the PAZ domain. Chem Commun (Camb) 46:4270-4272.
31. Strapps WR, Pickering V, Muiru GT, Rice J, Orsborn S, Polisky BA, Sachs A, and Bartz SR (2010) The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Res 38:4788-4797.
32. Tang F, Hajkova P, O'Carroll D, Lee C, Tarakhovsky A, Lao K, and Surani MA (2008) MicroRNAs are tightly associated with RNA-induced gene silencing complexes in vivo. Biochem Biophys Res Commun 372:24-29.
33. Tao W, Davide JP, Cai M, Zhang GJ, South VJ, Matter A, Ng B, Zhang Y, and Sepp-Lorenzino L (2010) Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther 18:1657-1666.
34. Tuschl T (2001) RNA interference and small interfering RNAs. Chembiochem 2:239-245.
35. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, and Maraganore J (2010) A status report on RNAi therapeutics. Silence 1:14.
36. Veldhoen S, Laufer SD, Trampe A, and Restle T (2006) Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 34:6561-6573. (Pubitemid 46017951)
37. Watts JK, Deleavey GF, and Damha MJ (2008) Chemically modified siRNA: tools and applications. Drug Discov Today 13:842-855.
38. Willmann JK, van Bruggen N, Dinkelborg LM, and Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591-607. (Pubitemid 351927724)
39. Wincott FE (2001) Strategies for oligoribonucleotide synthesis according to the phosphoramidite method. Curr Protoc Nucleic Acid Chem Chapter 3:Unit 3.5.
40. Zou Y, Tiller P, Chen IW, Beverly M, and Hochman J (2008) Metabolite identification of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun Mass Spectrom 22:1871-1881. (Pubitemid 351947753)